论文部分内容阅读
目的:评价孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入对小儿呼吸道感染性咳嗽的临床疗效。方法:选取2015年8月—2016年9月间收治的小儿呼吸道感染性咳嗽患儿78例临床资料,按照就诊顺序号将其分为观察组与对照组(每组39例);对照组患儿给予孟鲁司特钠片口服治疗,观察组患儿在对照组治疗基础上再加用异丙托溴铵和布地奈德混悬液雾化吸入治疗,评价两组患儿治疗后的总有效率和症状评分值及不良反应的发生率。结果:观察组患儿治疗后的总有效率为97.44%明显高于对照组为79.49%(P<0.05),治疗后的咽痒、咳嗽和咳痰的评分值均明显低于对照组(P<0.05);两组患儿用药期间不良反应的发生率经组间比较其差异无统计学意义(P>0.05)。结论:采用孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入治疗小儿呼吸道感染性咳嗽的临的临床疗效较显著,可有效地改善临床症状,安全性较高。
OBJECTIVE: To evaluate the clinical effect of inhalation of Montelukast sodium tablets, ipratropium bromide and budesonide suspension on children with respiratory tract infection cough. Methods: The clinical data of 78 children with respiratory tract infection cough from August 2015 to September 2016 were selected and divided into observation group and control group (39 cases in each group) Children given montelukast sodium tablets oral treatment, the observation group children in the control group based on the treatment plus ipratropium bromide and budesonide suspension atomization inhalation treatment, evaluation of two groups of children after treatment of total Efficacy and symptom scores and the incidence of adverse reactions. Results: The total effective rate of the observation group after treatment was 97.44%, which was significantly higher than that of the control group (79.49%, P <0.05). After treatment, the scores of pharyngitis, cough and sputum were significantly lower than those of the control group <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The clinical effect of using inhalation of Montelukast sodium tablets, ipratropium bromide and budesonide suspension for treatment of pediatric respiratory tract infection cough is significant, which can effectively improve the clinical symptoms and have higher safety .